Fig. 5
From: High resolution optical mapping of cardiac electrophysiology in pre-clinical models
Flecainide and carbenoxolone induced conduction slowing in mouse whole hearts. (a) Example activation maps from mouse whole heart at increasing concentrations of flecainide. (b) Grouped conduction velocity data from mouse whole heart at increasing concentrations of flecainide. (c) Example activation maps from mouse whole heart at increasing concentrations of carbenoxolone. (d) Grouped conduction velocity data from mouse whole heart at increasing concentrations of carbenoxolone. n = 6 for both experiments. One-way ANOVA, **P < 0.01, ***P < 0.001, ****P < 0.0001 against 0 µM flecainide/carbenoxolone respectively. Pacing cycle length = 110 ms.
